enfortumab,enfortumab vedotin
astellas,seagen
['ev-301', 'urothelial', 'enfortumab']
long-term outcomes in ev-301: 24-month findings from the phase 3 trial of enfortumab vedotin vs chemotherapy in patients with previously treated adv #urothelialcarcinoma. presented by . #asco22 written coverage &gt; 
Largest global online community of #urological medical professionals & patients. #AUA22 #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology